Literature DB >> 20544537

Biological efficiency of AMP deaminase inhibitor: 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydronaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5]-[1,3]diazepin-8-OL.

T Borkowski1, E M Slominska, C Orlewska, A H Y Yuen, S Al-Ayoubi, P Siondalski, M H Yacoub, R T Smolenski.   

Abstract

AMP deaminase could be a potential target for treatment of heart disease but experimental evaluation of this concept is difficult due to limited availability of inhibitors with proven efficiency in biological systems. This study evaluated the effect of 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydronaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo [4,5-d][1,3]diazepin-8-ol, an AMP deaminase inhibitor (AMPDI) on the pathways of nucleotide metabolism in perfused rat heart. We show that AMPDI at 0.3 mM concentration effectively inhibits AMP deaminase in this experimental model.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544537     DOI: 10.1080/15257771003741299

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  1 in total

Review 1.  AMP deaminase 1 gene polymorphism and heart disease-a genetic association that highlights new treatment.

Authors:  Ryszard T Smolenski; Iwona Rybakowska; Jacek Turyn; Paweł Romaszko; Magdalena Zabielska; Anne Taegtmeyer; Ewa M Słomińska; Krystian K Kaletha; Paul J R Barton
Journal:  Cardiovasc Drugs Ther       Date:  2014-04       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.